Projects per year
Personal profile
Biography
Professor Jian Li, FAA, FAAM, FAHMS
Professor Jian Li (PhD 2002) is an elected Fellow of the Australian Academy of Science, the Australian Academy of Health and Medical Science (AAHMS), and the American Academy of Microbiology. He is Head of the Antimicrobial Systems Pharmacology Laboratory at the Biomedicine Discovery Institute, Monash University. He is a Web of Science Highly Cited Researcher in Pharmacology & Toxicology (2015 - 2017, 2022). Dr Li has an internationally recognised track record in the pharmacology of polymyxins and the discovery of novel, safer antimicrobial peptides. He has 452 publications with 31,705 citations and an h-index of 85. His team has developed a novel lipopeptide drug BRII-693 (QPX9003) from concept to clinical trials to target MDR Gram-negative pathogens (NIH/NIAID). Excellent results of Phase-I clinical trials were featured in several presentations at the ID Week Meeting in Washington, DC (2022). Moreover, the majority of modern polymyxin pharmacology data are reported by Prof Li's group. His research has led to the first dosing guidelines of polymyxins which have been adopted worldwide and have significantly improved clinical practice. Dr Li's research is funded by the NIH, NHMRC, ARC, pharmaceutical companies and other grant bodies. Dr Li is Editor-in-Chief of The International Journal of Antimicrobial Agents. He is an invited reviewer for 198 international journals and grant/fellowship applications for the Australian National Health and Medical Research Council (NHMRC), Australian Research Council (ARC) and 26 international funding bodies (e.g. NIH/NIAID). Dr Li has received numerous awards, including Australian Leadership Award (2013), Australian National Health and Medical Research Council’s Ten of the Best Research Projects (2014) and Australian Academy of Science Jacques Miller Medal (2017).
Monash teaching commitment
Supervisor of PhD, Masters and Honours students
Research interests
Antibiotics are a cornerstone of modern medicine and over the last century have significantly decreased mortality worldwide. Unfortunately, resistance to these ‘magic bullets’ has become one of the greatest threats to human health that the world faces, now and in the coming decades. If proactive solutions are not found to prevent widespread antibiotic resistance, it is estimated that by 2050 ~10 million people per year will die of infections. The World Health Organization (WHO) has urged all government sectors and society to act on antimicrobial resistance (AMR). In 2017, multidrug-resistant Klebsiella pneumoniae, Pseudomonas aeruginosa and Acinetobacter baumannii were identified by WHO as the highest priority pathogens, which require urgent attention for the discovery of novel antibiotics. Over the last decade, ‘old’ polymyxins are increasingly used as the last defence against these Gram-negative ‘superbugs’ and unfortunately, resistance to polymyxins has been increasingly reported. As no new antibiotics will be available for Gram-negative ‘superbugs’ in the near future, it is crucial to optimise the clinical use of current antibiotics and develop novel therapies.
Expertise related to UN Sustainable Development Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):
Research area keywords
- Antimicrobial Resistance
- Drug Discovery
- Antimicrobial Pharmacology
- Systems Pharmacology
- Computational Biology
- Bioinformatics
- Polymyxin
- Colistin
- Pharmacodynamics
- Pharmacokinetics
- Acinetobacter baumannii
- Klebsiella pneumoniae
- Pseudomonas aeruginosa
Collaborations and top research areas from the last five years
-
A new mechanism of bacterial membrane defence against environmental stress
Han, M. (Primary Chief Investigator (PCI)), Li, J. (Chief Investigator (CI)) & Patil, N. (Chief Investigator (CI))
1/04/25 → 31/03/28
Project: Research
-
Aerosol delivery of combinational therapeutics targeting deadly lung infections
Zhou, Q. (Primary Chief Investigator (PCI)) & Li, J. (Chief Investigator (CI))
1/02/24 → 31/01/26
Project: Research
-
Drug Target Identification Platform
Creek, D. (Primary Chief Investigator (PCI)), Avery, V. M. (Chief Investigator (CI)), Pitson, S. M. (Chief Investigator (CI)), George, A. J. (Chief Investigator (CI)), Olechnowicz, S. (Chief Investigator (CI)), Baell, J. (Chief Investigator (CI)), Schittenhelm, R. (Chief Investigator (CI)), Li, J. (Chief Investigator (CI)), Langmead, C. (Chief Investigator (CI)), Stupple, P. (Chief Investigator (CI)), Drinkwater, C. (Chief Investigator (CI)), Flynn, B. (Chief Investigator (CI)), Brouwer, K. (Chief Investigator (CI)), Arndt, G. (Chief Investigator (CI)) & Newman, S. (Chief Investigator (CI))
Department of Health and Aged Care (Australia)
30/06/23 → 6/12/28
Project: Research
-
A novel dual therapy approach to treatment of multidrug-resistant Gram-negative infections
Ogunniyi, A. D. (Primary Chief Investigator (PCI)), Garg, S. (Chief Investigator (CI)), McCluskey, A. (Chief Investigator (CI)), Woolford, L. (Chief Investigator (CI)), Soares da Costa, T. P. (Chief Investigator (CI)), Ebrahimie, E. (Associate Investigator (AI)), McCluskey, A. (Associate Investigator (AI)), Trott, D. (Associate Investigator (AI)), Turnidge, J. (Associate Investigator (AI)) & Li, J. (Associate Investigator (AI))
1/04/23 → 31/03/26
Project: Research
-
Precise Combination Strategies Targeting Carbapenem-Resistant Klebsiella pneumoniae
Bulman, Z. P. (Primary Chief Investigator (PCI)), Mankin, A. S. (Chief Investigator (CI)), Bulitta, J. B. B. (Chief Investigator (CI)), Lang, Y. (Chief Investigator (CI)), Li, J. (Chief Investigator (CI)), Hauser, A. R. (Chief Investigator (CI)) & Ozer, E. A. (Chief Investigator (CI))
5/12/22 → 30/11/27
Project: Research
-
Advancing Nitrile-Aminothiol Strategy for Dual and Sequential Bioconjugation
Thombare, V. J., Wu, Y., Pamulapati, K., Han, M., Tailhades, J., Cryle, M. J., Roberts, K. D., Velkov, T., Li, J. & Patil, N. A., 19 Aug 2024, In: Chemistry - A European Journal. 30, 6, 10 p., e202401674.Research output: Contribution to journal › Article › Research › peer-review
Open Access2 Citations (Scopus) -
Arginine catabolism is essential to polymyxin dependence in Acinetobacter baumannii
Han, M.-L. (Leading Author), Alsaadi, Y., Zhao, J., Zhu, Y., Lu, J., Jiang, X., Ma, W., Patil, N. A., Dunstan, R. A., Le Brun, A. P., Wickremasinghe, H., Hu, X., Wu, Y., Yu, H. H., Wang, J., Barlow, C. K., Bergen, P. J., Shen, H.-H., Lithgow, T. & Creek, D. J. & 2 others, , 23 Jul 2024, In: Cell Reports. 43, 7, 21 p., 114410.Research output: Contribution to journal › Article › Research › peer-review
Open Access4 Citations (Scopus) -
Distinguishing Inducible and Non-Inducible Resistance to Colistin in Pseudomonas aeruginosa by Quantitative and Systems Pharmacology Modeling at Low and Standard Inocula
Bulitta, J. B., Shin, E., Bergen, P. J., Lang, Y., Forrest, A., Tsuji, B. T., Moya, B., Li, J., Nation, R. L. & Landersdorfer, C. B., Jan 2024, In: Journal of Pharmaceutical Sciences. 113, 1, p. 202-213 12 p.Research output: Contribution to journal › Article › Research › peer-review
3 Citations (Scopus) -
Erratum: Correction: Synergistic potential of Leu10-teixobactin and cefepime against multidrug-resistant Staphylococcus aureus (BMC microbiology (2024) 24 1 DOI: 10.1186/s12866-024-03577-x)
Koh, A. J. J., Hussein, M., Thombare, V., Crawford, S., Li, J. & Velkov, T., 11 Nov 2024, In: BMC Microbiology. 24, 1, 2 p., 464.Research output: Contribution to journal › Comment / Debate › Other › peer-review
Open Access -
High-level nitrofurantoin resistance in a clinical isolate of Klebsiella pneumoniae: a comparative genomics and metabolomics analysis
Hussein, M., Sun, Z., Hawkey, J., Allobawi, R., Judd, L. M., Carbone, V., Sharma, R., Thombare, V., Baker, M., Rao, G. G., Li, J., Holt, K. E. & Velkov, T., 23 Jan 2024, In: mSystems. 9, 1, 16 p., e00972-23.Research output: Contribution to journal › Article › Research › peer-review
Open Access4 Citations (Scopus)
Prizes
-
Team Award for Research Impact [Economic and Social] (Faculty of Pharmacy and Pharmaceutical Sciences, Monash University)
Nation, R. (Recipient), Velkov, T. (Recipient), Li, J. (Recipient), Roberts, K. (Recipient) & Thompson, P. (Recipient), 2016
Prize: Prize (including medals and awards)
-
Vice-Chancellor's Award for Excellence in Research Engagement and Impact (Monash University)
Nation, R. (Recipient), Li, J. (Recipient), Roberts, K. (Recipient), Velkov, T. (Recipient) & Thompson, P. (Recipient), 2022
Prize: Prize (including medals and awards)
Activities
- 1 Submissions to industry or govt committees, commissions and inquiries
-
Drug Delivery, Disposition and Dynamics
Jian Li (Member)
9 Nov 2011 → 9 Sept 2099Activity: External Academic Engagement › Submissions to industry or govt committees, commissions and inquiries
Press/Media
-
AI tool to boost genomic data analysis
Jiangning Song, Roger Daly & Jian Li
25/04/19
1 Media contribution
Press/Media: Research
-
Genome scale model of a superbug
Trevor Lithgow, Jian Li & Jiangning Song
16/03/18 → 30/03/18
2 Media contributions
Press/Media: Research
-
A$9.8 million fight against superbugs
Li, J., Charman, W. N., Song, J., Purcell, A. W., Hertzog, P. J., Creek, D. J., Nation, R. L., Bullita, J. & Boyce, J. D.
24/04/14
1 Media contribution
Press/Media: Public Engagement Activities